



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/517,208	12/08/2004	David Charles Gladman	1045-007	4353
36405 7590 01/19/2011 MANNAVA & KANG, P.C. 11240 WAPLES MILL ROAD Suite 300 FAIRFAX, VA 22030				
EXAMINER				
PALENIK, JEFFREY T				
ART UNIT		PAPER NUMBER		
1615				
MAIL DATE		DELIVERY MODE		
01/19/2011		PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/517,208

Applicant(s)

GLADMAN ET AL.

Examiner

Jeffrey T. Palenik

Art Unit

1615

Period for Reply -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 11 August 2010.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1, 2 and 4-25 is/are pending in the application.
- 4a) Of the above claim(s) 7-23 is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1, 2, 4-6, 24 and 25 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☒ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☒ All b) ☐ Some * c) ☐ None of:
1. ☒ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. _____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftperson's Patent Drawing Review (PTO-945)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____

DETAILED ACTION

STATUS OF THE APPLICATION

Receipt is acknowledged of Applicants' Request for Continued Examination (RCE), Amendments and Remarks, filed 11 August 2010, in the matter of Application N° 10/517,208. The Examiner further acknowledges the following:

Claims 1, 2, and 4-25 are pending, where claims 7-23 remain withdrawn from consideration.

No claims have been added or cancelled.

Claim 1 alone has been editorially amended.

No new matter has been added.

Thus, claims 1, 2, 4-6, 24 and 25 continue to represent all claims currently under consideration.

INFORMATION DISCLOSURE STATEMENT

No new Information Disclosure Statements (IDS) have been filed for consideration.

MAINTAINED REJECTIONS

The following rejections are maintained from the previous Office Correspondence dated 11 March 2010 since the art which was previously cited continues to read on the amended/newly cited limitations.

CLAIM REJECTIONS - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

The factual inquiries set forth in *Graham v. John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

1. Determining the scope and contents of the prior art.
2. Ascertaining the differences between the prior art and the claims at issue.
3. Resolving the level of ordinary skill in the pertinent art.
4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claim 1 is rejected under 35 U.S.C. 103(a) as being unpatentable over the combined teachings of Hiestand et al. (USPN 3,549,555) and Barnett et al. (USPN 4,999,198) further in view of Macaulay (USPN 3,016,308) and Wheeler (USPN 6,165,479).

The instantly amended base claim is drawn to a powder whose particles comprise biliquid foam droplets encapsulated by a polymeric matrix material. The droplets, which comprise both an oil and continuous phase and have a mean size ranging from 1-45 microns. The overall fine powder particles are recited as having a size range of 5-150 microns.

Hiestand teaches a process for encapsulating a hydrophobic liquid-in-aqueous liquid (e.g. oil-in-water) emulsion within a wall-forming polymeric material (Abstract). The "primary emulsion" is taught as referring to the lipophilic liquid-in-hydrophilic liquid emulsion, where either or both of the phases may have additional ingredients dissolved or suspended within (col. 4, lines 16-20) such as an active pharmaceutical, cosmetic or nutritional substance (col. 3, lines 60). The emulsion is further taught as comprising emulsifying agents such as sorbitan derivatives and polyoxyethylene derivatives (col. 4, lines 29-32). The wall-forming polymer material is taught as being composed of a macromolecular polymer whose key property is that it does not intermix with the external phase of the emulsion; the two are immiscible (col. 4, lines 65-71).

Regarding the instantly claimed dimensions, for both the inner droplet and the overall particle size, Hiestand is silent save for teaching that the size of the particle is dependent on two factors. First, the overall size is dependent on the degree of dispersion or size of the emulsion particles, and second, that the end particle size is a function of the thickness of the coacervate coating (e.g. the wall thickness). Hiestand is further silent to the use of a biliquid foam (e.g. polyaphrons) as the liquid which is encapsulated within the particles formed.

Barnett teaches the formation of polyaphron-based drug delivery systems wherein the drug is carried in the disperse phase (Abstract). Polyaphrons are defined as multi-phase systems consisting of a dispersion of suspended tiny droplets ranging in size between about one micron to about one millimeter encased in a continuous phase (col. 1, lines 22-25). The polyaphrons of the Barnett reference are specifically directed to those where water is the continuous phase and selected oils are the disperse or suspended phase. Either water- or oil-soluble surfactants may be incorporated into the system (col. 1, lines 55-65). Barnett also expressly suggests that a polymer matrix may be formed about the outside of the polyaphron in order to precisely control the release rate of the drug dispersed therein (col. 3, lines 53-61). These compounds are referred to as thickening agents and they are taught as including, for example, sodium alginate (col. 3, lines 39-41). It is further taught that when the continuous phase is aqueous other soluble polymeric thickening agents may include alginates and starches (col. 4, lines 1-3).

It would have been *prima facie* obvious to a person of ordinary skill in the art at the time the invention was made to have substituted the drug-loaded polyaphron composition which is taught by Barnett for the drug-loaded, oil-in-water emulsion which is coated in the invention of Hiestand. Polyaphrons (i.e. biliquid foams) and emulsions are taught in the art as being distinct compositions on the basis of the number of interfaces which separate the suspended or discontinuous phase from the continuous aqueous phase (see Sebba, USPN 4,486,333; col. 1, lines 31-47). However, despite this physical difference, the ordinarily skilled artisan would have been highly motivated to substitute a biliquid foam for an oil-in-water emulsion, particularly since the two compositions are chemically homologous. Both compositions fundamentally

contain an aqueous continuous phase, an oil-based discontinuous or droplet phase, and a surfactant. Thus the skilled artisan would have a reasonably high expectation that both compositions would be capable of encapsulation by a wall-forming polymeric material as taught by Hiestand. The skilled artisan would be further motivated to incorporate a biliquid foam particularly where it involves the administration of pharmaceuticals and/or cosmetic compositions embedded therein, as evidenced by Wheeler (USPN 6,165,479). Wheeler explains that a further disadvantage to using an emulsion is that the amount of surfactant is high enough to diminish the efficacy of many of the essential preservatives found within emulsion formulations. To overcome this, the amount of preservatives is increased ultimately resulting in skin-sensitization and exacerbation of skin problems (col. 1, lines 34-41). Thus, the advantage to using a biliquid foam over an emulsion, particularly for cosmetic or pharmaceutical purposes, stems from the basis that biliquid foams are less irritating due to their lower levels of surfactants (col. 2, lines 25-32).

Regarding the droplet and particle size ranges, Barnett expressly teaches that the polyaphron suspended phase consists of droplets which range in size from about one micron to one millimeter, as discussed above. However, none of the references expressly teach the size range of the overall powder particles, as claimed by Applicants. However, the values and formats for each these parameter with respect to the claimed composition are adjustable, it follows that each is a result-effective parameter that a person having ordinary skill in the art would routinely optimize. Optimization of parameters is a routine practice that would be obvious for a person of ordinary skill in the art to employ. For example, also as discussed above,

Hiestand expressly teaches that one of the factors contributing to the overall size of the discrete particles (e.g. encapsulated emulsion) is the degree to which the coacervate is allowed to form the wall about the emulsion. However, the formation of discrete particles containing a dispersible liquid in the size range claimed by Applicants is well-known in the art as evidenced by the teachings of Macaulay (USPN 3,016,308). Claim 11, for example, teaches a free-flowing powder of microscopic discrete rupturable capsules having a particle size ranging from about 0.1 microns to about 70 microns in diameter. The particles are taught as being formed from an emulsion which is later encased within a shell which may be formed from various film-forming polymers, some of which are well-known pharmaceutically acceptable compounds (e.g. casein, cellulose derivatives, carboxymethyl cellulose, etc.) (col. 5, lines 43-51). Thus, it would have been customary for an artisan of ordinary skill, to adjust the sizes of both the droplet and overall particle of the composition, particularly in view of Barnett and Macaulay, in order to achieve the desired discrete particles. Thus, absent some demonstration of unexpected results from the claimed parameters, optimization of any of these parameters would have been obvious at the time of Applicants' invention.

Claims 2 and 4 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hiestand et al. with respect to claim 1, as set for above.

Claim 2 recites that the powder composition which is formed is done so via spray-drying, freeze-drying (e.g. lyophilization) or fluidized bed granulation. The limitations of the claim are broadly and reasonably considered by the Examiner as being product-by-process limitations, which, per MPEP §2113 is an attempt to further limit an inventive composition in terms of the

means by which it is made. Despite this interpretation, the Examiner respectfully points out that Hiestand expressly teaches that preparation of the walled particles is followed with a drying step which may be accomplished using several different techniques which include either spray-drying or freeze-drying (col. 7, lines 17-23).

Claim 4 recites limitations to the polymeric material used to encapsulate the instantly claimed biliquid foam. The limitations of this claim are met where Hiestand teaches that the coacervate or wall-forming polymer(s) used include such compounds as gelatin and acacia (Ex. 3; col. 7, line 70 to col. 8, line 4; Ex. 1, col. 8, lines 60-67). Example 3 (col. 9, lines 30-55) also expressly teaches using sodium alginate to form the polymer-based wall.

The skilled artisan would have been highly motivated to incorporate the additional teachings of Hiestand, particularly in view of the aforementioned similarities between emulsions and biliquid foams. Given that the two compositions are similar in their chemical composition, as discussed above, the ordinarily skilled artisan would have a reasonable expectation of successfully encapsulating the biliquid foam using those polymeric wall-forming materials which are taught by Hiestand. It would have been prima facie obvious to a person of ordinary skill in the art at the time the invention was made to have formed the encapsulating wall using the polymers and drying techniques expressly taught by Hiestand to prepare the instantly claimed polymeric-encapsulated biliquid foam particles as instantly claimed.

Claims 5, 6, 24 and 25 are rejected under 35 U.S.C. 103(a) as being unpatentable over Hiestand et al., with respect to claim 1 as set forth above, as further evidenced by Wheeler (USPN 6,165,479).

Claim 5 recites limitations to the water-immiscible internal oil phase of the biliquid foam. Claim 6 recites that said oil is present between 5-50% by weight based on the weight of the ensuing powder. Claims 24 and 25 recite that the internal oil phase of the composition comprises different forms of active compounds such as pharmaceuticals.

Hiestand expressly teaches the limitations of claims 24 and 25 such that the encapsulated composition may have embedded within it a variety of materials designed to be controllably-released. Such compounds include nutritional compounds (e.g. vitamins), cosmetics, and pharmaceuticals (col. 3, lines 40-61). Regarding the limitations of claims 5 and 6, Hiestand teaches the use of oils such as lanolin, soybean and mineral oils (col. 4, lines 21-28). More specifically, Example 3 (col. 9) teaches the formation of an emulsion which comprises approximately 50% by weight of mineral oil. The formed emulsion particles are encapsulated within a sodium alginate polymeric wall and hardened via freeze-drying.

Thus, it would have been *prima facie* obvious to an artisan of ordinary skill at the time the invention was made to have incorporated a water-immiscible compound such as mineral oil in the amounts claimed by Applicants as well as an active pharmaceutical compound, and expect to arrive at the instantly claimed invention. The ordinarily skilled artisan would have been highly motivated to incorporate an oil such as mineral oil particularly in view of the aforementioned similarities between biliquid foams and emulsions. Further with regards to the

similarities between the two compositions, Wheeler teaches many of the instantly claimed oils which may be used to form the suspended droplets of a biliquid foam, namely lanolin, soybean and mineral oils (col. 2, lines 47-55) are the same as those which are expressly taught by Hiestand. Wheeler also teaches that biliquid foams are known in the art as containing up to 95% by volume of the oil component (col. 2, lines 15-20), a range which reads on and encompasses the amount which is instantly claimed. The teachings of Hiestand (Ex. 3, col. 9) teach incorporating approximately 50% by weight of mineral oil in the encapsulated emulsion.

Thus, based on the combined teachings of the references, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, alone or in combination, especially in the absence of evidence to the contrary.

RESPONSE TO ARGUMENTS

Applicants' arguments with regard to the rejection of claims 1, 2, 4-6, 24 and 25 under 35 USC 103(a) as being unpatentable over the combined teachings of Hiestand et al. and Barnett et al., with further evidence being provided by Macaulay et al. and Wheeler et al., have been fully considered but they are not persuasive.

Concerning the teachings of Hiestand, Applicants allege that the reference "does not teach or suggest a discrete powder" and that the "teaching of a capsule that is essentially free of surface moisture is not a teaching or suggestion of a discrete powder".

Concerning the Barnett reference, Applicants acknowledge on the record the teachings which disclose that the release rate of a drug from a polyaphron (e.g., biliquid foam) may be controlled by polymerization of either phase (i.e., the continuous phase) such as by the addition of monomers in order to obtain polymerization at the interface for release control. Applicants then allege that “there is no teaching or suggestion in Barnett of a matrix of polymeric material encapsulating droplets”.

Applicants lastly traverse the Macaulay and Wheeler references on the grounds that neither of the references teach or suggest the biliquid foam limitations of the claims or the instantly claimed mean particle size.

As an initial matter, in response to Applicants’ apparent arguments against the references individually, one cannot show nonobviousness by attacking references individually where the rejections are based on combinations of references. See *In re Keller*, 642 F.2d 413, 208 USPQ 871 (CCPA 1981); *In re Merck & Co.*, 800 F.2d 1091, 231 USPQ 375 (Fed. Cir. 1986). In the instant case, as an example, the Examiner respectfully points to Applicants’ apparent traversal of the combination of Barnett and Wheeler (e.g., Remarks, pg. 14, last full paragraph).

Secondly, Applicants’ provide remarks directed to the Examiner’s statement that the biliquid foam and emulsions being chemically homologous is incorrect (see pg. 11-12, bridging para.) and offer the Annex of the response filed 18 May 2009, as support.

The Examiner did consider said Annex and continues to respectfully disagree with Applicants. To be clear, the position that the Examiner set forth as a basis of the previous response was not that the a biliquid foam and emulsion are the same. Rather, the two are chemically homologous or similar enough chemically that the ordinarily skilled artisan would

reasonably expect the two compositions to function and behave in similar manners. In considering Applicants' Annex, the opening statement which is directed to defining a biliquid foam states that it is "as used herein ... a particular kind of hydrophobic liquid-in-hydrophilic liquid dispersion comprising (a) a hydrophilic miscible phase, (b) a second hydrophobic phase being immiscible or substantially immiscible with the first phase and (c) one or more surfactants, wherein the dispersed or discontinuous phase is in the form of small droplets. Even with consideration of their characteristics, the fundamental description of polyaphrons is considered to be similar to that of an emulsion (e.g., an oil-in-water emulsion).

The Examiner respectfully maintains that the rejection of claim 1, above, over the combined teachings of Hiestand and Barnett, in further evidence of Wheeler. Contrary to Applicants' assertions, Hiestand is directed to encapsulating lipophilic liquid-in-hydrophilic liquid compositions (emulsions) thereby forming solid encapsulated emulsion particles (see e.g., col. 3, lines 40-45). Barnett, as discussed above, is directed to polyaphrons whose drug release is controlled via a polymerized matrix which may be formed over the continuous phase. It is acknowledged, that Hiestand does not expressly disclose employing a biliquid foam in its particle encapsulation embodiments whereas Barnett does. As acknowledged by Applicants on the record, "Wheeler teaches that the advantage to choosing a biliquid foam over an emulsion stems from the basis that biliquid foams are less irritating to the skin as compared to emulsions because of their lower level of surfactants". Contrary to Applicants' assertion, Wheeler is not meant to teach all of the limitations of the instant invention. Rather the Examiner relies upon the reference to help remedy the deficiencies of Hiestand. Wheeler provides the teachings necessary to motivate the ordinarily skilled artisan to modify the teachings of Hiestand with Barnett,

namely motivating said artisan to substitute the more irritating drug delivery emulsion of Hiestand with the less irritating drug delivery biliquid foam of Barnett.

For these reasons, Applicants' arguments continue to be found unpersuasive. Said rejection is therefore **maintained**.

All claims under consideration remain rejected; no claims are allowed.

CONCLUSION

All claims are drawn to the same invention claimed in the application prior to the entry of the submission under 37 CFR 1.114 and could have been finally rejected on the grounds and art of record in the next Office action if they had been entered in the application prior to entry under 37 CFR 1.114. Accordingly, **THIS ACTION IS MADE FINAL** even though it is a first action after the filing of a request for continued examination and the submission under 37 CFR 1.114. See MPEP § 706.07(b). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however,

will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

CORRESPONDENCE

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jeffrey T. Palenik whose telephone number is (571) 270-1966. The examiner can normally be reached on 7:30 am - 5:00 pm; M-F (EST).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Robert A. Wax can be reached on (571) 272-0623. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Jeffrey T. Palenik/
Examiner, Art Unit 1615

/Robert A. Wax/
Supervisory Patent Examiner, Art Unit 1615